News

British pharmaceutical company GlaxoSmithKline on Wednesday said its annual performance should be better than expected, despite US tariffs, after sales of its cancer drugs jumped in the second quarter ...
Specialty Medicines delivered 15% growth to £3.3 billion, led by Respiratory, Immunology & Inflammation up 10%, Oncology up 42%, and HIV up 12%. CEO Emma Walmsley said the performance reflects “strong ...
Revenue in the second quarter of 2025 rose 1.3% to GBP7.99 billion from GBP7.88 billion, helping to push pretax profit up 26% to GBP1.89 billion from GBP1.50 billion. Core operating profit rose 12% at ...